Alexa Buffa - Corporate Communications

Jennifer Buell - President and Chief Executive Officer

Christine Klaskin - Principal Financial and Accounting Officer

Paul Ibbett - Scientist

Thank you for standing by. I would like to welcome everyone to the MiNK Therapeutics Third Quarter 2024 Financial Results. I would now like to turn the call over to Alexa Buffa from MiNK's Corporate Communications. Please go ahead.

Alexa Buffa

Thank you, operator, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, including those related to our clinical development, regulatory, and commercial plans, time for data releases, and partnership opportunities.

These statements are subject to risks and uncertainties. Please refer to our SEC filings available on our website for a detailed description of these risks. Joining me today are Dr. Jennifer Buell, President and Chief Executive Officer, Christine Klaskin, Principal Financial and Accounting Officer, Dr. Nils Rutquist [ph], Director of Research, and Dr. Paul Ibbett, Scientist at MiNK. Now, I'd like to turn the call over to Dr. Buell to highlight our progress from this quarter.

Jennifer Buell

Thank you, Alexa. Good morning, and thank you all for joining us today. Today, we will share progress and updates from the third quarter of this year, highlighting developments we've made in advancing our platform, actualizing the potential of this powerful subclass of T-cells, these allogeneic Invariant Natural Killer T-cells, or INKTs.

With our fully integrated discovery platform, engineering expertise and manufacturing innovation, we're poised to deliver what we believe to be the most scalable and transformative